Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Integrated Animals is a virtual database currently indexing available animal strains and mutants from: AGSC (Ambystoma), BCBC (mice), BDSC (flies), European Xenopus Resource Center (frog), The National Xenopus Resource (frog), Xenopus Express (frog), CWRU Cystic Fibrosis Mouse Models (mice), DGGR (flies), FlyBase (flies), IMSR (mice), MGI (mice), MMRRC (mice), NSRRC (pig), RGD (rats), Sperm Stem Cell Libraries for Biological Research (rats), Tetrahymena Stock Center (Tetrahymena), WormBase (worms), XGSC (Xiphophorus), ZFIN (zebrafish), and ZIRC (zebrafish). Note, the IMSR data is linked, but users may need to re-execute the search if the top mouse is not returned properly.
Note: BCBC is no longer in service, so the links may not be functional.
| Organism Name | Proper Citation | Species | Synonyms |
Notes |
Phenotype | Affected Gene | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MXH28/Mo-lpr/lpr Resource Report Resource Website Issue |
RRID:IMSR_RBRC11141 | Mus musculus |
MXH28-Fas |
gene symbol note: Fas cell surface death receptor; recombinant inbred: Fas | Fas cell surface death receptor | lymphoproliferation | RBRC11141 | RIKEN BioResource Research Center | RBRC | embryo | 2026-09-04 10:25:02 | 0 | ||||
|
MXH36/Mo-lpr/lpr Resource Report Resource Website Issue |
RRID:IMSR_RBRC11142 | Mus musculus |
MXH36-Fas |
gene symbol note: Fas cell surface death receptor; recombinant inbred: Fas | Fas cell surface death receptor | lymphoproliferation | RBRC11142 | RIKEN BioResource Research Center | RBRC | embryo | 2026-09-04 10:25:02 | 0 | ||||
|
MXH7/Mo-lpr/lpr Resource Report Resource Website Issue |
RRID:IMSR_RBRC11152 | Mus musculus |
MXH7-Fas |
gene symbol note: Fas cell surface death receptor; recombinant congenic: Fas | Fas cell surface death receptor | lymphoproliferation | RBRC11152 | RIKEN BioResource Research Center | RBRC | embryo | 2026-09-04 10:25:02 | 0 | ||||
|
MXH10/Mo-lpr/lpr Resource Report Resource Website 1+ mentions Issue |
RRID:IMSR_RBRC11153 | Mus musculus |
MXH10-Fas |
gene symbol note: Fas cell surface death receptor; recombinant congenic: Fas | Fas cell surface death receptor | lymphoproliferation | RBRC11153 | RIKEN BioResource Research Center | RBRC | embryo | 2026-09-04 10:25:02 | 6 | ||||
|
McH/Mo-lpr/lpr-RA1 Resource Report Resource Website Issue |
RRID:IMSR_RBRC11160 | Mus musculus |
MRL(C3H)-Fas |
gene symbol note: Fas cell surface death receptor; recombinant congenic: Fas | Fas cell surface death receptor | lymphoproliferation | RBRC11160 | RIKEN BioResource Research Center | RBRC | embryo | 2026-09-04 10:25:02 | 0 | ||||
|
STOCK Prnptm1Cwe Tg(Prnp*)CDah/Cnrm Resource Report Resource Website Issue Issue |
RRID:IMSR_EM:06142 | Mus musculus |
STOCK Prnp |
gene symbol note: transgene insertion C; David A Harris|prion protein; mutant strain: Tg(Prnp*)CDah|Prnp | transgene insertion C; David A Harris|prion protein | transgene insertion C; David A Harris|targeted mutation 1; Charles Weissmann | EM:06142 | European Mouse Mutant Archive | EMMA | embryo | 2026-09-04 10:33:11 | 0 | ||||
|
STOCK Rag2tm1Fwa B2m Resource Report Resource Website Issue Issue Issue |
RRID:IMSR_EM:06326 | Mus musculus |
SURE-L1/Rag2°/°GammaC°/°. STOCK Rag2 |
gene symbol note: recombination activating gene 2|beta-2 microglobulin|transgene insertion 1; Daniel M Altmann|histocompatibility 2; class II antigen A; beta 1|transgene insertion 1; Beatrice Perarnau|interleukin 2 receptor; gamma chain; mutant strain: Rag2|B2m|Tg(HLA-DRA*0101;HLA-DRB1*0101)1Dma|H2-Ab1|Tg(HLA-A/H2-D/B2M)1Bpe|Il2rg | recombination activating gene 2|beta-2 microglobulin|transgene insertion 1; Daniel M Altmann|histocompatibility 2; class II antigen A; beta 1|transgene insertion 1; Beatrice Perarnau|interleukin 2 receptor; gamma chain | targeted mutation 1; Frederick W Alt|targeted mutation 1; University of North Carolina|transgene insertion 1; Daniel M Altmann|targeted mutation 1; Christophe Benoist and Diane Mathis|transgene insertion 1; Beatrice Perarnau|targeted mutation 1; Kazuo Sugamura | EM:06326 | European Mouse Mutant Archive | EMMA | archived | 2026-09-04 10:33:12 | 0 | ||||
|
STOCK Rag2tm1Fwa B2m Resource Report Resource Website Issue |
RRID:IMSR_EM:06943 | Mus musculus |
STOCK Rag2 |
gene symbol note: recombination activating gene 2|perforin 1 (pore forming protein)|histocompatibility 2; class II antigen A; beta 1|transgene insertion 1; Daniel M Altmann|beta-2 microglobulin|transgene insertion 1; Beatrice Perarnau; mutant strain: Rag2|Prf1|H2-Ab1|Tg(HLA-DRA*0101;HLA-DRB1*0101)1Dma|B2m|Tg(HLA-A/H2-D/B2M)1Bpe | recombination activating gene 2|perforin 1 (pore forming protein)|histocompatibility 2; class II antigen A; beta 1|transgene insertion 1; Daniel M Altmann|beta-2 microglobulin|transgene insertion 1; Beatrice Perarnau | targeted mutation 1; Frederick W Alt|targeted mutation 1; Sandoz Pharmaceuticals|targeted mutation 1; Christophe Benoist and Diane Mathis|transgene insertion 1; Daniel M Altmann|targeted mutation 1; University of North Carolina|transgene insertion 1; Beatrice Perarnau | EM:06943 | European Mouse Mutant Archive | EMMA | embryo | 2026-09-04 10:33:14 | 0 | ||||
|
MRL.Cg-Ccr1tm1Gao Ccr5 Resource Report Resource Website Issue |
RRID:IMSR_EM:08425 | Mus musculus | 15L-M | gene symbol note: Fas cell surface death receptor|C-C motif chemokine receptor 1|C-C motif chemokine receptor 5; mutant strain: Fas|Ccr1|Ccr5 | Fas cell surface death receptor|C-C motif chemokine receptor 1|C-C motif chemokine receptor 5 | lymphoproliferation|targeted mutation 1; Ji-Liang Gao|targeted mutation 1; Bruno Luckow | EM:08425 | European Mouse Mutant Archive | EMMA | sperm | 2026-09-04 10:33:27 | 0 | ||||
|
y[1] sc[*] v[1] sev[21]; P{y[+t7.7] v[+t1.8]=TRiP.HMS00609}attP2 Resource Report Resource Website 50+ mentions Issue |
RRID:BDSC_34393 | Drosophila melanogaster | Donor: Transgenic RNAi Project | Sxl, UAS, sc, sev, v, y | Chromosome 1, Chromosome 3 | 34393 | Bloomington Drosophila Stock Center (BDSC) | BDSC | available | BDSC_34393, BDSC:34393, BL34393 | 2026-09-05 07:03:56 | 69 | ||||
|
B6.129S4-Atp8b1tm1Nbf/Mmucd Resource Report Resource Website Issue |
RRID:MMRRC_036310-UCD | Mus musculus | Research areas: Cell Biology, Internal/Organ, Metabolism, Models for Human Disease, Sensorineural; Mutation Type: Targeted Mutation ; Collection: | abnormal cochlea morphology [MP:0000031]| organ of Corti degeneration [MP:0000043]| enlarged liver [MP:0000599]| abnormal liver physiology [MP:0000609]| cholestasis [MP:0000610]| weight loss [MP:0001263]| postnatal growth retardation [MP:0001732]| abnormal cochlear ganglion morphology [MP:0002855]| increased circulating alanine transaminase level [MP:0002941]| increased circulating alkaline phosphatase level [MP:0002968]| increased liver weight [MP:0002981]| bile duct proliferation [MP:0003255]| cochlear inner hair cell degeneration [MP:0004398]| cochlear outer hair cell degeneration [MP:0004404]| degeneration of organ of Corti supporting cells [MP:0004465]| abnormal outer hair cell stereociliary bundle morphology [MP:0004527]| abnormal bile secretion [MP:0004772]| abnormal bile salt level [MP:0004774]| increased bile salt level [MP:0004789]| increased circulating aspartate transaminase level [MP:0005343]| increased circulating bilirubin level [MP:0005344]| abnormal bile salt homeostasis [MP:0005365]| increased sensitivity to induced morbidity/mortality [MP:0009763]| increased susceptibility to weight loss [MP:0010180]| increased or absent threshold for auditory brainstem response [MP:0011967] | Atp8b1 | 036310-UCD | Targeted Mutation | Mutant Mouse Resource and Research Center (MMRRC) | MMRRC | PMID:20126555 PMID:18466903 |
MMRRC_36310-UCD, MMRRC_036310, MMRRC_3631 | 2026-09-05 04:09:19 | 0 | |||
|
129S/Sv-Atp8b1tm1Nbf/Mmucd Resource Report Resource Website Issue |
RRID:MMRRC_036309-UCD | Mus musculus | Research areas: Cell Biology, Internal/Organ, Metabolism, Models for Human Disease, Sensorineural; Mutation Type: Targeted Mutation ; Collection: | abnormal cochlea morphology [MP:0000031]| organ of Corti degeneration [MP:0000043]| enlarged liver [MP:0000599]| abnormal liver physiology [MP:0000609]| cholestasis [MP:0000610]| weight loss [MP:0001263]| postnatal growth retardation [MP:0001732]| abnormal cochlear ganglion morphology [MP:0002855]| increased circulating alanine transaminase level [MP:0002941]| increased circulating alkaline phosphatase level [MP:0002968]| increased liver weight [MP:0002981]| bile duct proliferation [MP:0003255]| cochlear inner hair cell degeneration [MP:0004398]| cochlear outer hair cell degeneration [MP:0004404]| degeneration of organ of Corti supporting cells [MP:0004465]| abnormal outer hair cell stereociliary bundle morphology [MP:0004527]| abnormal bile secretion [MP:0004772]| abnormal bile salt level [MP:0004774]| increased bile salt level [MP:0004789]| increased circulating aspartate transaminase level [MP:0005343]| increased circulating bilirubin level [MP:0005344]| abnormal bile salt homeostasis [MP:0005365]| increased sensitivity to induced morbidity/mortality [MP:0009763]| increased susceptibility to weight loss [MP:0010180]| increased or absent threshold for auditory brainstem response [MP:0011967] | Atp8b1 | 036309-UCD | Targeted Mutation | Mutant Mouse Resource and Research Center (MMRRC) | MMRRC | PMID:20126555 PMID:18466903 |
MMRRC_36309-UCD, MMRRC_036309, MMRRC_3639 | 2026-09-05 04:09:19 | 0 | |||
|
NOD.Cg-Ifngtm1Ts H2h4/HbmMmmh Resource Report Resource Website 1+ mentions Issue |
RRID:MMRRC_037140-MU | Mus musculus | Research areas: Immunology and Inflammation; Mutation Type: Targeted Mutation ; Collection: Mullen | increased leukocyte cell number [MP:0000218]| increased monocyte cell number [MP:0000220]| extramedullary hematopoiesis [MP:0000240]| increased granulocyte number [MP:0000322]| abnormal spleen morphology [MP:0000689]| enlarged spleen [MP:0000691]| abnormal lymph node size [MP:0000701]| enlarged lymph nodes [MP:0000702]| increased body weight [MP:0001260]| decreased body weight [MP:0001262]| increased metastatic potential [MP:0001272]| abnormal response to new environment [MP:0001413]| altered susceptibility to infection [MP:0001793]| abnormal humoral immune response [MP:0001800]| decreased IgG level [MP:0001805]| decreased IgM level [MP:0001806]| decreased IgA level [MP:0001807]| abnormal inflammatory response [MP:0001845]| increased inflammatory response [MP:0001846]| brain inflammation [MP:0001847]| kidney inflammation [MP:0001859]| liver inflammation [MP:0001860]| lung inflammation [MP:0001861]| stomach inflammation [MP:0001873]| decreased inflammatory response [MP:0001876]| abnormal lactation [MP:0001882]| mammary gland alveolar hyperplasia [MP:0001884]| decreased litter size [MP:0001935]| abnormal lung volume [MP:0001942]| increased airway responsiveness [MP:0001952]| emphysema [MP:0001958]| increased B cell derived lymphoma incidence [MP:0002023]| increased T cell derived lymphoma incidence [MP:0002024]| increased lung adenocarcinoma incidence [MP:0002027]| increased sarcoma incidence [MP:0002032]| increased carcinoma incidence [MP:0002038]| increased pituitary adenoma incidence [MP:0002041]| decreased tumor incidence [MP:0002052]| premature death [MP:0002083]| abnormal spleen size [MP:0002224]| abnormal pulmonary alveolus morphology [MP:0002270]| decreased airway responsiveness [MP:0002335]| abnormal lymph node cortex morphology [MP:0002343]| abnormal lymph node primary follicle morphology [MP:0002345]| abnormal lymph node secondary follicle morphology [MP:0002346]| abnormal spleen red pulp morphology [MP:0002356]| abnormal spleen white pulp morphology [MP:0002357]| abnormal dendritic cell physiology [MP:0002376]| increased susceptibility to bacterial infection [MP:0002412]| increased susceptibility to viral infection [MP:0002418]| abnormal adaptive immunity [MP:0002420]| altered susceptibility to autoimmune disorder [MP:0002425]| abnormal macrophage physiology [MP:0002451]| abnormal dendritic cell antigen presentation [MP:0002455]| abnormal B cell physiology [MP:0002459]| decreased immunoglobulin level [MP:0002460]| increased immunoglobulin level [MP:0002461]| abnormal immunoglobulin level [MP:0002490]| decreased IgE level [MP:0002492]| increased IgE level [MP:0002497]| abnormal type IV hypersensitivity reaction [MP:0002534]| glomerulonephritis [MP:0002743]| decreased vertical activity [MP:0002757]| albuminuria [MP:0002871]| increased circulating alanine transaminase level [MP:0002941]| abnormal cytokine secretion [MP:0003009]| abnormal redox activity [MP:0003186]| small intestinal inflammation [MP:0003306]| abnormal tumor morphology [MP:0003448]| increased fear-related response [MP:0003459]| abnormal pancreatic beta cell physiology [MP:0003562]| increased ovarian carcinoma incidence [MP:0003579]| increased autoantibody level [MP:0003725]| decreased autoantibody level [MP:0003726]| abnormal nitric oxide homeostasis [MP:0003957]| abnormal lung vasculature morphology [MP:0004007]| abnormal maternal decidual layer morphology [MP:0004256]| decreased length of allograft survival [MP:0004752]| decreased anti-nuclear antigen antibody level [MP:0004795]| decreased anti-double stranded DNA antibody level [MP:0004798]| increased susceptibility to experimental autoimmune encephalomyelitis [MP:0004799]| decreased susceptibility to systemic lupus erythematosus [MP:0004802]| decreased susceptibility to autoimmune diabetes [MP:0004804]| abnormal immune tolerance [MP:0005000]| increased eosinophil cell number [MP:0005011]| increased lymphocyte cell number [MP:0005013]| increased T cell number [MP:0005015]| abnormal response to infection [MP:0005025]| decreased susceptibility to parasitic infection [MP:0005026]| increased susceptibility to parasitic infection [MP:0005027]| abnormal MHC II cell surface expression on macrophages [MP:0005040]| impaired natural killer cell mediated cytotoxicity [MP:0005070]| abnormal cytotoxic T cell physiology [MP:0005078]| decreased double-negative T cell number [MP:0005089]| cachexia [MP:0005150]| abnormal response to injury [MP:0005164]| decreased susceptibility to injury [MP:0005166]| abnormal renal glomerulus morphology [MP:0005325]| atherosclerotic lesions [MP:0005338]| decreased susceptibility to autoimmune disorder [MP:0005351]| abnormal Langerhans cell physiology [MP:0005362]| increased susceptibility to fungal infection [MP:0005399]| abnormal skin physiology [MP:0005501]| corneal vascularization [MP:0005542]| decreased circulating creatinine level [MP:0005554]| increased blood urea nitrogen level [MP:0005565]| decreased susceptibility to type IV hypersensitivity reaction [MP:0005616]| increased susceptibility to type IV hypersensitivity reaction [MP:0005617]| abnormal response to transplant [MP:0005671]| abnormal mammary gland growth during pregnancy [MP:0006269]| increased NK T cell number [MP:0008039]| abnormal uterine NK cell morphology [MP:0008054]| increased CD4-positive [MP:0008074]| alpha beta T cell number [MP:0008078]| increased CD8-positive [MP:0008135]| alpha-beta T cell number [MP:0008466]| small Peyer's patches [MP:0008474]| enlarged mesenteric lymph nodes [MP:0008496]| absent spleen germinal center [MP:0008497]| decreased IgG2a level [MP:0008498]| decreased IgG2b level [MP:0008499]| decreased IgG3 level [MP:0008523]| increased IgG1 level [MP:0008567]| absent lymph node germinal center [MP:0008596]| decreased interferon-gamma secretion [MP:0008660]| increased circulating interleukin-6 level [MP:0008661]| increased interleukin-10 secretion [MP:0008663]| decreased interleukin-10 secretion [MP:0008681]| increased interleukin-12 secretion [MP:0008687]| increased interleukin-17 secretion [MP:0008699]| increased interleukin-2 secretion [MP:0008702]| increased interleukin-4 secretion [MP:0008713]| increased interleukin-5 secretion [MP:0008770]| abnormal cytokine level [MP:0008828]| decreased survivor rate [MP:0008874]| abnormal lymph node cell ratio [MP:0009099]| decreased physiological sensitivity to xenobiotic [MP:0009246]| abnormal uterine NK cell physiology [MP:0009336]| pale spleen [MP:0009394]| increased splenocyte proliferation [MP:0009419]| increased uterine NK cell number [MP:0009643]| skeletal muscle fibrosis [MP:0009763]| abnormal urine homeostasis [MP:0009766]| increased sensitivity to induced morbidity/mortality [MP:0009788]| increased sensitivity to xenobiotic induced morbidity/mortality [MP:0009791]| increased susceptibility to bacterial infection induced morbidity/mortality [MP:0009828]| increased susceptibility to viral infection induced morbidity/mortality [MP:0010210]| increased tumor latency [MP:0010308]| abnormal circulating cytokine level [MP:0010574]| decreased tumor latency [MP:0010639]| aorta dilation [MP:0010659]| altered tumor pathology [MP:0010740]| abdominal aorta aneurysm [MP:0010750]| abnormal dendritic cell chemotaxis [MP:0010751]| increased susceptibility to parasitic infection induced morbidity/mortality [MP:0010760]| decreased susceptibility to parasitic infection induced morbidity/mortality [MP:0010766]| abnormal macrophage chemotaxis [MP:0011086]| abnormal NK cell physiology [MP:0011320]| postnatal lethality [MP:0011427]| incomplete penetrance [MP:0012431]| abnormal glomerular capillary morphology [MP:0013239]| mesangial cell hyperplasia [MP:0013590]| increased lymphoma incidence [MP:0030466]| abnormal cytokine secretion [MP:0003009]| thyroid inflammation [MP:0003504]| insulitis [MP:0004031]| decreased susceptibility to autoimmune diabetes [MP:0004804]| periinsulitis [MP:0005580]| decreased physiological sensitivity to xenobiotic [MP:0008874] | Ifng | 037140-MU | Targeted Mutation | Mutant Mouse Resource and Research Center (MMRRC) | MMRRC | PMID:16394017 PMID:21220693 PMID:22119715 PMID:23509363 PMID:25400914 PMID:12244202 |
MMRRC_37140-MU, MMRRC_037140, MMRRC_3714 | 2026-09-05 04:09:28 | 2 | |||
|
NOD.Cg-Pdcd1tm1.1Shr Ifngtm1Ts H2h4/HbmMmmh Resource Report Resource Website 1+ mentions Issue |
RRID:MMRRC_037145-MU | Mus musculus | Research areas: Immunology and Inflammation; Mutation Type: Targeted Mutation ; Collection: Mullen | increased leukocyte cell number [MP:0000218]| increased monocyte cell number [MP:0000220]| extramedullary hematopoiesis [MP:0000240]| increased granulocyte number [MP:0000322]| abnormal spleen morphology [MP:0000689]| enlarged spleen [MP:0000691]| abnormal lymph node size [MP:0000701]| enlarged lymph nodes [MP:0000702]| increased body weight [MP:0001260]| decreased body weight [MP:0001262]| increased metastatic potential [MP:0001272]| abnormal response to new environment [MP:0001413]| altered susceptibility to infection [MP:0001793]| abnormal humoral immune response [MP:0001800]| decreased IgG level [MP:0001805]| decreased IgM level [MP:0001806]| decreased IgA level [MP:0001807]| abnormal inflammatory response [MP:0001845]| increased inflammatory response [MP:0001846]| brain inflammation [MP:0001847]| kidney inflammation [MP:0001859]| liver inflammation [MP:0001860]| lung inflammation [MP:0001861]| stomach inflammation [MP:0001873]| decreased inflammatory response [MP:0001876]| abnormal lactation [MP:0001882]| mammary gland alveolar hyperplasia [MP:0001884]| decreased litter size [MP:0001935]| abnormal lung volume [MP:0001942]| increased airway responsiveness [MP:0001952]| emphysema [MP:0001958]| increased B cell derived lymphoma incidence [MP:0002023]| increased T cell derived lymphoma incidence [MP:0002024]| increased lung adenocarcinoma incidence [MP:0002027]| increased sarcoma incidence [MP:0002032]| increased carcinoma incidence [MP:0002038]| increased pituitary adenoma incidence [MP:0002041]| decreased tumor incidence [MP:0002052]| premature death [MP:0002083]| abnormal spleen size [MP:0002224]| abnormal pulmonary alveolus morphology [MP:0002270]| decreased airway responsiveness [MP:0002335]| abnormal lymph node cortex morphology [MP:0002343]| abnormal lymph node primary follicle morphology [MP:0002345]| abnormal lymph node secondary follicle morphology [MP:0002346]| abnormal spleen red pulp morphology [MP:0002356]| abnormal spleen white pulp morphology [MP:0002357]| abnormal dendritic cell physiology [MP:0002376]| increased susceptibility to bacterial infection [MP:0002412]| increased susceptibility to viral infection [MP:0002418]| abnormal adaptive immunity [MP:0002420]| altered susceptibility to autoimmune disorder [MP:0002425]| abnormal macrophage physiology [MP:0002451]| abnormal dendritic cell antigen presentation [MP:0002455]| abnormal B cell physiology [MP:0002459]| decreased immunoglobulin level [MP:0002460]| increased immunoglobulin level [MP:0002461]| abnormal immunoglobulin level [MP:0002490]| decreased IgE level [MP:0002492]| increased IgE level [MP:0002497]| abnormal type IV hypersensitivity reaction [MP:0002534]| glomerulonephritis [MP:0002743]| decreased vertical activity [MP:0002757]| albuminuria [MP:0002871]| increased circulating alanine transaminase level [MP:0002941]| abnormal cytokine secretion [MP:0003009]| abnormal redox activity [MP:0003186]| small intestinal inflammation [MP:0003306]| abnormal tumor morphology [MP:0003448]| increased fear-related response [MP:0003459]| abnormal pancreatic beta cell physiology [MP:0003562]| increased ovarian carcinoma incidence [MP:0003579]| increased autoantibody level [MP:0003725]| decreased autoantibody level [MP:0003726]| abnormal nitric oxide homeostasis [MP:0003957]| abnormal lung vasculature morphology [MP:0004007]| abnormal maternal decidual layer morphology [MP:0004256]| decreased length of allograft survival [MP:0004752]| decreased anti-nuclear antigen antibody level [MP:0004795]| decreased anti-double stranded DNA antibody level [MP:0004798]| increased susceptibility to experimental autoimmune encephalomyelitis [MP:0004799]| decreased susceptibility to systemic lupus erythematosus [MP:0004802]| decreased susceptibility to autoimmune diabetes [MP:0004804]| abnormal immune tolerance [MP:0005000]| increased eosinophil cell number [MP:0005011]| increased lymphocyte cell number [MP:0005013]| increased T cell number [MP:0005015]| abnormal response to infection [MP:0005025]| decreased susceptibility to parasitic infection [MP:0005026]| increased susceptibility to parasitic infection [MP:0005027]| abnormal MHC II cell surface expression on macrophages [MP:0005040]| impaired natural killer cell mediated cytotoxicity [MP:0005070]| abnormal cytotoxic T cell physiology [MP:0005078]| decreased double-negative T cell number [MP:0005089]| cachexia [MP:0005150]| abnormal response to injury [MP:0005164]| decreased susceptibility to injury [MP:0005166]| abnormal renal glomerulus morphology [MP:0005325]| atherosclerotic lesions [MP:0005338]| decreased susceptibility to autoimmune disorder [MP:0005351]| abnormal Langerhans cell physiology [MP:0005362]| increased susceptibility to fungal infection [MP:0005399]| abnormal skin physiology [MP:0005501]| corneal vascularization [MP:0005542]| decreased circulating creatinine level [MP:0005554]| increased blood urea nitrogen level [MP:0005565]| decreased susceptibility to type IV hypersensitivity reaction [MP:0005616]| increased susceptibility to type IV hypersensitivity reaction [MP:0005617]| abnormal response to transplant [MP:0005671]| abnormal mammary gland growth during pregnancy [MP:0006269]| increased NK T cell number [MP:0008039]| abnormal uterine NK cell morphology [MP:0008054]| increased CD4-positive [MP:0008074]| alpha beta T cell number [MP:0008078]| increased CD8-positive [MP:0008135]| alpha-beta T cell number [MP:0008466]| small Peyer's patches [MP:0008474]| enlarged mesenteric lymph nodes [MP:0008496]| absent spleen germinal center [MP:0008497]| decreased IgG2a level [MP:0008498]| decreased IgG2b level [MP:0008499]| decreased IgG3 level [MP:0008523]| increased IgG1 level [MP:0008567]| absent lymph node germinal center [MP:0008596]| decreased interferon-gamma secretion [MP:0008660]| increased circulating interleukin-6 level [MP:0008661]| increased interleukin-10 secretion [MP:0008663]| decreased interleukin-10 secretion [MP:0008681]| increased interleukin-12 secretion [MP:0008687]| increased interleukin-17 secretion [MP:0008699]| increased interleukin-2 secretion [MP:0008702]| increased interleukin-4 secretion [MP:0008713]| increased interleukin-5 secretion [MP:0008770]| abnormal cytokine level [MP:0008828]| decreased survivor rate [MP:0008874]| abnormal lymph node cell ratio [MP:0009099]| decreased physiological sensitivity to xenobiotic [MP:0009246]| abnormal uterine NK cell physiology [MP:0009336]| pale spleen [MP:0009394]| increased splenocyte proliferation [MP:0009419]| increased uterine NK cell number [MP:0009643]| skeletal muscle fibrosis [MP:0009763]| abnormal urine homeostasis [MP:0009766]| increased sensitivity to induced morbidity/mortality [MP:0009788]| increased sensitivity to xenobiotic induced morbidity/mortality [MP:0009791]| increased susceptibility to bacterial infection induced morbidity/mortality [MP:0009828]| increased susceptibility to viral infection induced morbidity/mortality [MP:0010210]| increased tumor latency [MP:0010308]| abnormal circulating cytokine level [MP:0010574]| decreased tumor latency [MP:0010639]| aorta dilation [MP:0010659]| altered tumor pathology [MP:0010740]| abdominal aorta aneurysm [MP:0010750]| abnormal dendritic cell chemotaxis [MP:0010751]| increased susceptibility to parasitic infection induced morbidity/mortality [MP:0010760]| decreased susceptibility to parasitic infection induced morbidity/mortality [MP:0010766]| abnormal macrophage chemotaxis [MP:0011086]| abnormal NK cell physiology [MP:0011320]| postnatal lethality [MP:0011427]| incomplete penetrance [MP:0012431]| abnormal glomerular capillary morphology [MP:0013239]| mesangial cell hyperplasia [MP:0013590]| increased lymphoma incidence [MP:0030466]| abnormal cytokine secretion [MP:0003009]| thyroid inflammation [MP:0003504]| insulitis [MP:0004031]| decreased susceptibility to autoimmune diabetes [MP:0004804]| periinsulitis [MP:0005580]| decreased physiological sensitivity to xenobiotic [MP:0008874]| vasculitis [MP:0001864]| pancreas inflammation [MP:0001869]| increased retinal ganglion cell number [MP:0002983]| insulitis [MP:0004031]| increased susceptibility to autoimmune diabetes [MP:0004803]| increased regulatory T cell number [MP:0004973]| decreased B-1 B cell number [MP:0004978]| abnormal immune tolerance [MP:0005000]| decreased T cell proliferation [MP:0005095]| increased T cell proliferation [MP:0005348] | |Pdcd1||Ifng|| | 037145-MU | Targeted Mutation | Mutant Mouse Resource and Research Center (MMRRC) | MMRRC | MMRRC_37145-MU, MMRRC_037145, MMRRC_37145 | 2026-09-05 04:09:28 | 1 | ||||
|
NOD.Cg-Ifngtm1Ts Ighmtm1Cgn H2h4/HbmMmmh Resource Report Resource Website Issue Issue Issue |
RRID:MMRRC_037144-MU | Mus musculus | Research areas: Immunology and Inflammation; Mutation Type: Targeted Mutation ; Collection: Mullen | abnormal cytokine secretion [MP:0003009]| thyroid inflammation [MP:0003504]| insulitis [MP:0004031]| decreased susceptibility to autoimmune diabetes [MP:0004804]| periinsulitis [MP:0005580]| decreased physiological sensitivity to xenobiotic [MP:0008874]| decreased bone mineral density [MP:0000063]| abnormal trabecular bone morphology [MP:0000130]| decreased compact bone thickness [MP:0000135]| enlarged heart [MP:0000274]| increased cell proliferation [MP:0000351]| abnormal intestinal epithelium morphology [MP:0000488]| abnormal spleen morphology [MP:0000689]| enlarged lymph nodes [MP:0000702]| abnormal skin condition [MP:0001191]| abnormal cardiovascular system physiology [MP:0001544]| abnormal humoral immune response [MP:0001800]| arrested B cell differentiation [MP:0001802]| decreased IgG level [MP:0001805]| decreased IgM level [MP:0001806]| decreased IgA level [MP:0001807]| thymus hypoplasia [MP:0001823]| abnormal antigen presentation [MP:0001835]| abnormal inflammatory response [MP:0001845]| increased inflammatory response [MP:0001846]| heart inflammation [MP:0001853]| myocarditis [MP:0001856]| kidney inflammation [MP:0001859]| abnormal lymphatic vessel morphology [MP:0001879]| premature death [MP:0002083]| abnormal respiratory system physiology [MP:0002133]| abnormal B cell differentiation [MP:0002144]| abnormal spleen marginal sinus morphology [MP:0002363]| abnormal B lymphocyte antigen presentation [MP:0002453]| decreased immunoglobulin level [MP:0002460]| abnormal immunoglobulin level [MP:0002490]| decreased IgE level [MP:0002492]| tubular nephritis [MP:0002704]| increased urine protein level [MP:0002962]| abnormal cytokine secretion [MP:0003009]| cardiac fibrosis [MP:0003141]| thrombocytopenia [MP:0003179]| small intestinal inflammation [MP:0003306]| increased susceptibility to induced arthritis [MP:0003724]| increased autoantibody level [MP:0003725]| abnormal compact bone morphology [MP:0003797]| abnormal PR interval [MP:0003901]| insulitis [MP:0004031]| decreased susceptibility to systemic lupus erythematosus [MP:0004802]| increased susceptibility to autoimmune diabetes [MP:0004803]| decreased susceptibility to autoimmune diabetes [MP:0004804]| decreased spleen weight [MP:0004953]| increased osteoclast cell number [MP:0004984]| increased T cell number [MP:0005015]| decreased B cell number [MP:0005017]| abnormal response to infection [MP:0005025]| increased susceptibility to parasitic infection [MP:0005027]| abnormal T cell proliferation [MP:0005094]| decreased T cell proliferation [MP:0005095]| cachexia [MP:0005150]| decreased susceptibility to injury [MP:0005166]| abnormal pancreatic islet morphology [MP:0005215]| abnormal CD4-positive [MP:0005463]| alpha-beta T cell physiology [MP:0005559]| increased circulating glucose level [MP:0005616]| decreased susceptibility to type IV hypersensitivity reaction [MP:0006387]| abnormal T cell number [MP:0008071]| absent B cells [MP:0008075]| decreased CD4-positive [MP:0008079]| alpha beta T cell number [MP:0008127]| decreased CD8-positive [MP:0008171]| alpha-beta T cell number [MP:0008201]| decreased dendritic cell number [MP:0008211]| abnormal mature B cell morphology [MP:0008212]| absent follicular dendritic cells [MP:0008213]| decreased mature B cell number [MP:0008240]| absent mature B cells [MP:0008241]| absent immature B cells [MP:0008401]| abnormal spleen marginal zone macrophage morphology [MP:0008470]| abnormal metallophilic macrophage morphology [MP:0008495]| abnormal CD8 positive [MP:0009346]| alpha-beta intraepithelial T cell morphology [MP:0010965]| abnormal spleen B cell follicle morphology [MP:0012431]| increased leukocyte cell number [MP:0000218]| increased monocyte cell number [MP:0000220]| extramedullary hematopoiesis [MP:0000240]| increased granulocyte number [MP:0000322]| abnormal spleen morphology [MP:0000689]| enlarged spleen [MP:0000691]| abnormal lymph node size [MP:0000701]| enlarged lymph nodes [MP:0000702]| increased body weight [MP:0001260]| decreased body weight [MP:0001262]| increased metastatic potential [MP:0001272]| abnormal response to new environment [MP:0001413]| altered susceptibility to infection [MP:0001793]| abnormal humoral immune response [MP:0001800]| decreased IgG level [MP:0001805]| decreased IgM level [MP:0001806]| decreased IgA level [MP:0001807]| abnormal inflammatory response [MP:0001845]| increased inflammatory response [MP:0001846]| brain inflammation [MP:0001847]| kidney inflammation [MP:0001859]| liver inflammation [MP:0001860]| lung inflammation [MP:0001861]| stomach inflammation [MP:0001873]| decreased inflammatory response [MP:0001876]| abnormal lactation [MP:0001882]| mammary gland alveolar hyperplasia [MP:0001884]| decreased litter size [MP:0001935]| abnormal lung volume [MP:0001942]| increased airway responsiveness [MP:0001952]| emphysema [MP:0001958]| increased B cell derived lymphoma incidence [MP:0002023]| increased T cell derived lymphoma incidence [MP:0002024]| increased lung adenocarcinoma incidence [MP:0002027]| increased sarcoma incidence [MP:0002032]| increased carcinoma incidence [MP:0002038]| increased pituitary adenoma incidence [MP:0002041]| decreased tumor incidence [MP:0002052]| premature death [MP:0002083]| abnormal spleen size [MP:0002224]| abnormal pulmonary alveolus morphology [MP:0002270]| decreased airway responsiveness [MP:0002335]| abnormal lymph node cortex morphology [MP:0002343]| abnormal lymph node primary follicle morphology [MP:0002345]| abnormal lymph node secondary follicle morphology [MP:0002346]| abnormal spleen red pulp morphology [MP:0002356]| abnormal spleen white pulp morphology [MP:0002357]| abnormal dendritic cell physiology [MP:0002376]| increased susceptibility to bacterial infection [MP:0002412]| increased susceptibility to viral infection [MP:0002418]| abnormal adaptive immunity [MP:0002420]| altered susceptibility to autoimmune disorder [MP:0002425]| abnormal macrophage physiology [MP:0002451]| abnormal dendritic cell antigen presentation [MP:0002455]| abnormal B cell physiology [MP:0002459]| decreased immunoglobulin level [MP:0002460]| increased immunoglobulin level [MP:0002461]| abnormal immunoglobulin level [MP:0002490]| decreased IgE level [MP:0002492]| increased IgE level [MP:0002497]| abnormal type IV hypersensitivity reaction [MP:0002534]| glomerulonephritis [MP:0002743]| decreased vertical activity [MP:0002757]| albuminuria [MP:0002871]| increased circulating alanine transaminase level [MP:0002941]| abnormal cytokine secretion [MP:0003009]| abnormal redox activity [MP:0003186]| small intestinal inflammation [MP:0003306]| abnormal tumor morphology [MP:0003448]| increased fear-related response [MP:0003459]| abnormal pancreatic beta cell physiology [MP:0003562]| increased ovarian carcinoma incidence [MP:0003579]| increased autoantibody level [MP:0003725]| decreased autoantibody level [MP:0003726]| abnormal nitric oxide homeostasis [MP:0003957]| abnormal lung vasculature morphology [MP:0004007]| abnormal maternal decidual layer morphology [MP:0004256]| decreased length of allograft survival [MP:0004752]| decreased anti-nuclear antigen antibody level [MP:0004795]| decreased anti-double stranded DNA antibody level [MP:0004798]| increased susceptibility to experimental autoimmune encephalomyelitis [MP:0004799]| decreased susceptibility to systemic lupus erythematosus [MP:0004802]| decreased susceptibility to autoimmune diabetes [MP:0004804]| abnormal immune tolerance [MP:0005000]| increased eosinophil cell number [MP:0005011]| increased lymphocyte cell number [MP:0005013]| increased T cell number [MP:0005015]| abnormal response to infection [MP:0005025]| decreased susceptibility to parasitic infection [MP:0005026]| increased susceptibility to parasitic infection [MP:0005027]| abnormal MHC II cell surface expression on macrophages [MP:0005040]| impaired natural killer cell mediated cytotoxicity [MP:0005070]| abnormal cytotoxic T cell physiology [MP:0005078]| decreased double-negative T cell number [MP:0005089]| cachexia [MP:0005150]| abnormal response to injury [MP:0005164]| decreased susceptibility to injury [MP:0005166]| abnormal renal glomerulus morphology [MP:0005325]| atherosclerotic lesions [MP:0005338]| decreased susceptibility to autoimmune disorder [MP:0005351]| abnormal Langerhans cell physiology [MP:0005362]| increased susceptibility to fungal infection [MP:0005399]| abnormal skin physiology [MP:0005501]| corneal vascularization [MP:0005542]| decreased circulating creatinine level [MP:0005554]| increased blood urea nitrogen level [MP:0005565]| decreased susceptibility to type IV hypersensitivity reaction [MP:0005616]| increased susceptibility to type IV hypersensitivity reaction [MP:0005617]| abnormal response to transplant [MP:0005671]| abnormal mammary gland growth during pregnancy [MP:0006269]| increased NK T cell number [MP:0008039]| abnormal uterine NK cell morphology [MP:0008054]| increased CD4-positive [MP:0008074]| alpha beta T cell number [MP:0008078]| increased CD8-positive [MP:0008135]| alpha-beta T cell number [MP:0008466]| small Peyer's patches [MP:0008474]| enlarged mesenteric lymph nodes [MP:0008496]| absent spleen germinal center [MP:0008497]| decreased IgG2a level [MP:0008498]| decreased IgG2b level [MP:0008499]| decreased IgG3 level [MP:0008523]| increased IgG1 level [MP:0008567]| absent lymph node germinal center [MP:0008596]| decreased interferon-gamma secretion [MP:0008660]| increased circulating interleukin-6 level [MP:0008661]| increased interleukin-10 secretion [MP:0008663]| decreased interleukin-10 secretion [MP:0008681]| increased interleukin-12 secretion [MP:0008687]| increased interleukin-17 secretion [MP:0008699]| increased interleukin-2 secretion [MP:0008702]| increased interleukin-4 secretion [MP:0008713]| increased interleukin-5 secretion [MP:0008770]| abnormal cytokine level [MP:0008828]| decreased survivor rate [MP:0008874]| abnormal lymph node cell ratio [MP:0009099]| decreased physiological sensitivity to xenobiotic [MP:0009246]| abnormal uterine NK cell physiology [MP:0009336]| pale spleen [MP:0009394]| increased splenocyte proliferation [MP:0009419]| increased uterine NK cell number [MP:0009643]| skeletal muscle fibrosis [MP:0009763]| abnormal urine homeostasis [MP:0009766]| increased sensitivity to induced morbidity/mortality [MP:0009788]| increased sensitivity to xenobiotic induced morbidity/mortality [MP:0009791]| increased susceptibility to bacterial infection induced morbidity/mortality [MP:0009828]| increased susceptibility to viral infection induced morbidity/mortality [MP:0010210]| increased tumor latency [MP:0010308]| abnormal circulating cytokine level [MP:0010574]| decreased tumor latency [MP:0010639]| aorta dilation [MP:0010659]| altered tumor pathology [MP:0010740]| abdominal aorta aneurysm [MP:0010750]| abnormal dendritic cell chemotaxis [MP:0010751]| increased susceptibility to parasitic infection induced morbidity/mortality [MP:0010760]| decreased susceptibility to parasitic infection induced morbidity/mortality [MP:0010766]| abnormal macrophage chemotaxis [MP:0011086]| abnormal NK cell physiology [MP:0011320]| postnatal lethality [MP:0011427]| incomplete penetrance [MP:0012431]| abnormal glomerular capillary morphology [MP:0013239]| mesangial cell hyperplasia [MP:0013590]| increased lymphoma incidence [MP:0030466] | Ighm||Ifng||| | 037144-MU | Targeted Mutation | Mutant Mouse Resource and Research Center (MMRRC) | MMRRC | PMID:23509363 | MMRRC_37144-MU, MMRRC_037144, MMRRC_37144 | 2026-09-05 04:09:28 | 0 | |||
|
NOD.Cg-Cd40tm1Kik Ifngtm1Ts H2h4 Tg(tetO-Tcra)1Doi/HbmMmmh Resource Report Resource Website Issue |
RRID:MMRRC_037149-MU | Mus musculus | Research areas: Immunology and Inflammation; Mutation Type: Targeted Mutation ; Collection: Mullen | increased leukocyte cell number [MP:0000218]| increased monocyte cell number [MP:0000220]| extramedullary hematopoiesis [MP:0000240]| increased granulocyte number [MP:0000322]| abnormal spleen morphology [MP:0000689]| enlarged spleen [MP:0000691]| abnormal lymph node size [MP:0000701]| enlarged lymph nodes [MP:0000702]| increased body weight [MP:0001260]| decreased body weight [MP:0001262]| increased metastatic potential [MP:0001272]| abnormal response to new environment [MP:0001413]| altered susceptibility to infection [MP:0001793]| abnormal humoral immune response [MP:0001800]| decreased IgG level [MP:0001805]| decreased IgM level [MP:0001806]| decreased IgA level [MP:0001807]| abnormal inflammatory response [MP:0001845]| increased inflammatory response [MP:0001846]| brain inflammation [MP:0001847]| kidney inflammation [MP:0001859]| liver inflammation [MP:0001860]| lung inflammation [MP:0001861]| stomach inflammation [MP:0001873]| decreased inflammatory response [MP:0001876]| abnormal lactation [MP:0001882]| mammary gland alveolar hyperplasia [MP:0001884]| decreased litter size [MP:0001935]| abnormal lung volume [MP:0001942]| increased airway responsiveness [MP:0001952]| emphysema [MP:0001958]| increased B cell derived lymphoma incidence [MP:0002023]| increased T cell derived lymphoma incidence [MP:0002024]| increased lung adenocarcinoma incidence [MP:0002027]| increased sarcoma incidence [MP:0002032]| increased carcinoma incidence [MP:0002038]| increased pituitary adenoma incidence [MP:0002041]| decreased tumor incidence [MP:0002052]| premature death [MP:0002083]| abnormal spleen size [MP:0002224]| abnormal pulmonary alveolus morphology [MP:0002270]| decreased airway responsiveness [MP:0002335]| abnormal lymph node cortex morphology [MP:0002343]| abnormal lymph node primary follicle morphology [MP:0002345]| abnormal lymph node secondary follicle morphology [MP:0002346]| abnormal spleen red pulp morphology [MP:0002356]| abnormal spleen white pulp morphology [MP:0002357]| abnormal dendritic cell physiology [MP:0002376]| increased susceptibility to bacterial infection [MP:0002412]| increased susceptibility to viral infection [MP:0002418]| abnormal adaptive immunity [MP:0002420]| altered susceptibility to autoimmune disorder [MP:0002425]| abnormal macrophage physiology [MP:0002451]| abnormal dendritic cell antigen presentation [MP:0002455]| abnormal B cell physiology [MP:0002459]| decreased immunoglobulin level [MP:0002460]| increased immunoglobulin level [MP:0002461]| abnormal immunoglobulin level [MP:0002490]| decreased IgE level [MP:0002492]| increased IgE level [MP:0002497]| abnormal type IV hypersensitivity reaction [MP:0002534]| glomerulonephritis [MP:0002743]| decreased vertical activity [MP:0002757]| albuminuria [MP:0002871]| increased circulating alanine transaminase level [MP:0002941]| abnormal cytokine secretion [MP:0003009]| abnormal redox activity [MP:0003186]| small intestinal inflammation [MP:0003306]| abnormal tumor morphology [MP:0003448]| increased fear-related response [MP:0003459]| abnormal pancreatic beta cell physiology [MP:0003562]| increased ovarian carcinoma incidence [MP:0003579]| increased autoantibody level [MP:0003725]| decreased autoantibody level [MP:0003726]| abnormal nitric oxide homeostasis [MP:0003957]| abnormal lung vasculature morphology [MP:0004007]| abnormal maternal decidual layer morphology [MP:0004256]| decreased length of allograft survival [MP:0004752]| decreased anti-nuclear antigen antibody level [MP:0004795]| decreased anti-double stranded DNA antibody level [MP:0004798]| increased susceptibility to experimental autoimmune encephalomyelitis [MP:0004799]| decreased susceptibility to systemic lupus erythematosus [MP:0004802]| decreased susceptibility to autoimmune diabetes [MP:0004804]| abnormal immune tolerance [MP:0005000]| increased eosinophil cell number [MP:0005011]| increased lymphocyte cell number [MP:0005013]| increased T cell number [MP:0005015]| abnormal response to infection [MP:0005025]| decreased susceptibility to parasitic infection [MP:0005026]| increased susceptibility to parasitic infection [MP:0005027]| abnormal MHC II cell surface expression on macrophages [MP:0005040]| impaired natural killer cell mediated cytotoxicity [MP:0005070]| abnormal cytotoxic T cell physiology [MP:0005078]| decreased double-negative T cell number [MP:0005089]| cachexia [MP:0005150]| abnormal response to injury [MP:0005164]| decreased susceptibility to injury [MP:0005166]| abnormal renal glomerulus morphology [MP:0005325]| atherosclerotic lesions [MP:0005338]| decreased susceptibility to autoimmune disorder [MP:0005351]| abnormal Langerhans cell physiology [MP:0005362]| increased susceptibility to fungal infection [MP:0005399]| abnormal skin physiology [MP:0005501]| corneal vascularization [MP:0005542]| decreased circulating creatinine level [MP:0005554]| increased blood urea nitrogen level [MP:0005565]| decreased susceptibility to type IV hypersensitivity reaction [MP:0005616]| increased susceptibility to type IV hypersensitivity reaction [MP:0005617]| abnormal response to transplant [MP:0005671]| abnormal mammary gland growth during pregnancy [MP:0006269]| increased NK T cell number [MP:0008039]| abnormal uterine NK cell morphology [MP:0008054]| increased CD4-positive [MP:0008074]| alpha beta T cell number [MP:0008078]| increased CD8-positive [MP:0008135]| alpha-beta T cell number [MP:0008466]| small Peyer's patches [MP:0008474]| enlarged mesenteric lymph nodes [MP:0008496]| absent spleen germinal center [MP:0008497]| decreased IgG2a level [MP:0008498]| decreased IgG2b level [MP:0008499]| decreased IgG3 level [MP:0008523]| increased IgG1 level [MP:0008567]| absent lymph node germinal center [MP:0008596]| decreased interferon-gamma secretion [MP:0008660]| increased circulating interleukin-6 level [MP:0008661]| increased interleukin-10 secretion [MP:0008663]| decreased interleukin-10 secretion [MP:0008681]| increased interleukin-12 secretion [MP:0008687]| increased interleukin-17 secretion [MP:0008699]| increased interleukin-2 secretion [MP:0008702]| increased interleukin-4 secretion [MP:0008713]| increased interleukin-5 secretion [MP:0008770]| abnormal cytokine level [MP:0008828]| decreased survivor rate [MP:0008874]| abnormal lymph node cell ratio [MP:0009099]| decreased physiological sensitivity to xenobiotic [MP:0009246]| abnormal uterine NK cell physiology [MP:0009336]| pale spleen [MP:0009394]| increased splenocyte proliferation [MP:0009419]| increased uterine NK cell number [MP:0009643]| skeletal muscle fibrosis [MP:0009763]| abnormal urine homeostasis [MP:0009766]| increased sensitivity to induced morbidity/mortality [MP:0009788]| increased sensitivity to xenobiotic induced morbidity/mortality [MP:0009791]| increased susceptibility to bacterial infection induced morbidity/mortality [MP:0009828]| increased susceptibility to viral infection induced morbidity/mortality [MP:0010210]| increased tumor latency [MP:0010308]| abnormal circulating cytokine level [MP:0010574]| decreased tumor latency [MP:0010639]| aorta dilation [MP:0010659]| altered tumor pathology [MP:0010740]| abdominal aorta aneurysm [MP:0010750]| abnormal dendritic cell chemotaxis [MP:0010751]| increased susceptibility to parasitic infection induced morbidity/mortality [MP:0010760]| decreased susceptibility to parasitic infection induced morbidity/mortality [MP:0010766]| abnormal macrophage chemotaxis [MP:0011086]| abnormal NK cell physiology [MP:0011320]| postnatal lethality [MP:0011427]| incomplete penetrance [MP:0012431]| abnormal glomerular capillary morphology [MP:0013239]| mesangial cell hyperplasia [MP:0013590]| increased lymphoma incidence [MP:0030466]| decreased bone mineral density [MP:0000063]| decreased neutrophil cell number [MP:0000222]| enlarged spleen [MP:0000691]| enlarged lymph nodes [MP:0000702]| abnormal humoral immune response [MP:0001800]| decreased IgA level [MP:0001807]| no abnormal phenotype detected [MP:0002169]| abnormal thymus medulla morphology [MP:0002375]| abnormal dendritic cell physiology [MP:0002376]| increased susceptibility to bacterial infection [MP:0002412]| abnormal B cell physiology [MP:0002459]| decreased immunoglobulin level [MP:0002460]| decreased IgE level [MP:0002492]| glomerulonephritis [MP:0002743]| increased urine protein level [MP:0002962]| increased anti-double stranded DNA antibody level [MP:0004762]| abnormal class switch recombination [MP:0004816]| decreased B cell number [MP:0005017]| decreased susceptibility to type II hypersensitivity reaction [MP:0005612]| decreased cerebral infarction size [MP:0006058]| increased follicular B cell number [MP:0008173]| absent germinal center B cells [MP:0008179]| increased marginal zone B cell number [MP:0008181]| increased transitional stage B cell number [MP:0008189]| abnormal B cell activation [MP:0008217]| absent spleen germinal center [MP:0008474]| decreased IgG1 level [MP:0008495]| decreased IgG2a level [MP:0008496]| decreased IgG2b level [MP:0008497]| decreased IgG3 level [MP:0008498]| abnormal thymus epithelium morphology [MP:0009544]| decreased platelet aggregation [MP:0009549]| decreased trabecular bone mass [MP:0010873]| decreased compact bone mass [MP:0010962]| renal glomerular immunoglobulin deposits [MP:0020519]| abnormal cytokine secretion [MP:0003009]| thyroid inflammation [MP:0003504]| insulitis [MP:0004031]| decreased susceptibility to autoimmune diabetes [MP:0004804]| periinsulitis [MP:0005580]| decreased physiological sensitivity to xenobiotic [MP:0008874] | Cd40||Ifng|||| | 037149-MU | Targeted Mutation | Mutant Mouse Resource and Research Center (MMRRC) | MMRRC | MMRRC_37149-MU, MMRRC_037149, MMRRC_37149 | 2026-09-05 04:09:28 | 0 | ||||
|
NOD.Cg-Ighmtm1Cgn H2h4 Tg(Foxp3-HBEGF/EGFP)1Doi/HbmMmmh Resource Report Resource Website Issue Issue Issue |
RRID:MMRRC_037354-MU | Mus musculus | Research areas: ; Mutation Type: Targeted Mutation ; Collection: Mullen | decreased bone mineral density [MP:0000063]| abnormal trabecular bone morphology [MP:0000130]| decreased compact bone thickness [MP:0000135]| enlarged heart [MP:0000274]| increased cell proliferation [MP:0000351]| abnormal intestinal epithelium morphology [MP:0000488]| abnormal spleen morphology [MP:0000689]| enlarged lymph nodes [MP:0000702]| abnormal skin condition [MP:0001191]| abnormal cardiovascular system physiology [MP:0001544]| abnormal humoral immune response [MP:0001800]| arrested B cell differentiation [MP:0001802]| decreased IgG level [MP:0001805]| decreased IgM level [MP:0001806]| decreased IgA level [MP:0001807]| thymus hypoplasia [MP:0001823]| abnormal antigen presentation [MP:0001835]| abnormal inflammatory response [MP:0001845]| increased inflammatory response [MP:0001846]| heart inflammation [MP:0001853]| myocarditis [MP:0001856]| kidney inflammation [MP:0001859]| abnormal lymphatic vessel morphology [MP:0001879]| premature death [MP:0002083]| abnormal respiratory system physiology [MP:0002133]| abnormal B cell differentiation [MP:0002144]| abnormal spleen marginal sinus morphology [MP:0002363]| abnormal B lymphocyte antigen presentation [MP:0002453]| decreased immunoglobulin level [MP:0002460]| abnormal immunoglobulin level [MP:0002490]| decreased IgE level [MP:0002492]| tubular nephritis [MP:0002704]| increased urine protein level [MP:0002962]| abnormal cytokine secretion [MP:0003009]| cardiac fibrosis [MP:0003141]| thrombocytopenia [MP:0003179]| small intestinal inflammation [MP:0003306]| increased susceptibility to induced arthritis [MP:0003724]| increased autoantibody level [MP:0003725]| abnormal compact bone morphology [MP:0003797]| abnormal PR interval [MP:0003901]| insulitis [MP:0004031]| decreased susceptibility to systemic lupus erythematosus [MP:0004802]| increased susceptibility to autoimmune diabetes [MP:0004803]| decreased susceptibility to autoimmune diabetes [MP:0004804]| decreased spleen weight [MP:0004953]| increased osteoclast cell number [MP:0004984]| increased T cell number [MP:0005015]| decreased B cell number [MP:0005017]| abnormal response to infection [MP:0005025]| increased susceptibility to parasitic infection [MP:0005027]| abnormal T cell proliferation [MP:0005094]| decreased T cell proliferation [MP:0005095]| cachexia [MP:0005150]| decreased susceptibility to injury [MP:0005166]| abnormal pancreatic islet morphology [MP:0005215]| abnormal CD4-positive [MP:0005463]| alpha-beta T cell physiology [MP:0005559]| increased circulating glucose level [MP:0005616]| decreased susceptibility to type IV hypersensitivity reaction [MP:0006387]| abnormal T cell number [MP:0008071]| absent B cells [MP:0008075]| decreased CD4-positive [MP:0008079]| alpha beta T cell number [MP:0008127]| decreased CD8-positive [MP:0008171]| alpha-beta T cell number [MP:0008201]| decreased dendritic cell number [MP:0008211]| abnormal mature B cell morphology [MP:0008212]| absent follicular dendritic cells [MP:0008213]| decreased mature B cell number [MP:0008240]| absent mature B cells [MP:0008241]| absent immature B cells [MP:0008401]| abnormal spleen marginal zone macrophage morphology [MP:0008470]| abnormal metallophilic macrophage morphology [MP:0008495]| abnormal CD8 positive [MP:0009346]| alpha-beta intraepithelial T cell morphology [MP:0010965]| abnormal spleen B cell follicle morphology [MP:0012431]| increased leukocyte cell number [MP:0000218]| increased monocyte cell number [MP:0000220]| extramedullary hematopoiesis [MP:0000240]| increased granulocyte number [MP:0000322]| abnormal spleen morphology [MP:0000689]| enlarged spleen [MP:0000691]| abnormal lymph node size [MP:0000701]| enlarged lymph nodes [MP:0000702]| increased body weight [MP:0001260]| decreased body weight [MP:0001262]| increased metastatic potential [MP:0001272]| abnormal response to new environment [MP:0001413]| altered susceptibility to infection [MP:0001793]| abnormal humoral immune response [MP:0001800]| decreased IgG level [MP:0001805]| decreased IgM level [MP:0001806]| decreased IgA level [MP:0001807]| abnormal inflammatory response [MP:0001845]| increased inflammatory response [MP:0001846]| brain inflammation [MP:0001847]| kidney inflammation [MP:0001859]| liver inflammation [MP:0001860]| lung inflammation [MP:0001861]| stomach inflammation [MP:0001873]| decreased inflammatory response [MP:0001876]| abnormal lactation [MP:0001882]| mammary gland alveolar hyperplasia [MP:0001884]| decreased litter size [MP:0001935]| abnormal lung volume [MP:0001942]| increased airway responsiveness [MP:0001952]| emphysema [MP:0001958]| increased B cell derived lymphoma incidence [MP:0002023]| increased T cell derived lymphoma incidence [MP:0002024]| increased lung adenocarcinoma incidence [MP:0002027]| increased sarcoma incidence [MP:0002032]| increased carcinoma incidence [MP:0002038]| increased pituitary adenoma incidence [MP:0002041]| decreased tumor incidence [MP:0002052]| premature death [MP:0002083]| abnormal spleen size [MP:0002224]| abnormal pulmonary alveolus morphology [MP:0002270]| decreased airway responsiveness [MP:0002335]| abnormal lymph node cortex morphology [MP:0002343]| abnormal lymph node primary follicle morphology [MP:0002345]| abnormal lymph node secondary follicle morphology [MP:0002346]| abnormal spleen red pulp morphology [MP:0002356]| abnormal spleen white pulp morphology [MP:0002357]| abnormal dendritic cell physiology [MP:0002376]| increased susceptibility to bacterial infection [MP:0002412]| increased susceptibility to viral infection [MP:0002418]| abnormal adaptive immunity [MP:0002420]| altered susceptibility to autoimmune disorder [MP:0002425]| abnormal macrophage physiology [MP:0002451]| abnormal dendritic cell antigen presentation [MP:0002455]| abnormal B cell physiology [MP:0002459]| decreased immunoglobulin level [MP:0002460]| increased immunoglobulin level [MP:0002461]| abnormal immunoglobulin level [MP:0002490]| decreased IgE level [MP:0002492]| increased IgE level [MP:0002497]| abnormal type IV hypersensitivity reaction [MP:0002534]| glomerulonephritis [MP:0002743]| decreased vertical activity [MP:0002757]| albuminuria [MP:0002871]| increased circulating alanine transaminase level [MP:0002941]| abnormal cytokine secretion [MP:0003009]| abnormal redox activity [MP:0003186]| small intestinal inflammation [MP:0003306]| abnormal tumor morphology [MP:0003448]| increased fear-related response [MP:0003459]| abnormal pancreatic beta cell physiology [MP:0003562]| increased ovarian carcinoma incidence [MP:0003579]| increased autoantibody level [MP:0003725]| decreased autoantibody level [MP:0003726]| abnormal nitric oxide homeostasis [MP:0003957]| abnormal lung vasculature morphology [MP:0004007]| abnormal maternal decidual layer morphology [MP:0004256]| decreased length of allograft survival [MP:0004752]| decreased anti-nuclear antigen antibody level [MP:0004795]| decreased anti-double stranded DNA antibody level [MP:0004798]| increased susceptibility to experimental autoimmune encephalomyelitis [MP:0004799]| decreased susceptibility to systemic lupus erythematosus [MP:0004802]| decreased susceptibility to autoimmune diabetes [MP:0004804]| abnormal immune tolerance [MP:0005000]| increased eosinophil cell number [MP:0005011]| increased lymphocyte cell number [MP:0005013]| increased T cell number [MP:0005015]| abnormal response to infection [MP:0005025]| decreased susceptibility to parasitic infection [MP:0005026]| increased susceptibility to parasitic infection [MP:0005027]| abnormal MHC II cell surface expression on macrophages [MP:0005040]| impaired natural killer cell mediated cytotoxicity [MP:0005070]| abnormal cytotoxic T cell physiology [MP:0005078]| decreased double-negative T cell number [MP:0005089]| cachexia [MP:0005150]| abnormal response to injury [MP:0005164]| decreased susceptibility to injury [MP:0005166]| abnormal renal glomerulus morphology [MP:0005325]| atherosclerotic lesions [MP:0005338]| decreased susceptibility to autoimmune disorder [MP:0005351]| abnormal Langerhans cell physiology [MP:0005362]| increased susceptibility to fungal infection [MP:0005399]| abnormal skin physiology [MP:0005501]| corneal vascularization [MP:0005542]| decreased circulating creatinine level [MP:0005554]| increased blood urea nitrogen level [MP:0005565]| decreased susceptibility to type IV hypersensitivity reaction [MP:0005616]| increased susceptibility to type IV hypersensitivity reaction [MP:0005617]| abnormal response to transplant [MP:0005671]| abnormal mammary gland growth during pregnancy [MP:0006269]| increased NK T cell number [MP:0008039]| abnormal uterine NK cell morphology [MP:0008054]| increased CD4-positive [MP:0008074]| alpha beta T cell number [MP:0008078]| increased CD8-positive [MP:0008135]| alpha-beta T cell number [MP:0008466]| small Peyer's patches [MP:0008474]| enlarged mesenteric lymph nodes [MP:0008496]| absent spleen germinal center [MP:0008497]| decreased IgG2a level [MP:0008498]| decreased IgG2b level [MP:0008499]| decreased IgG3 level [MP:0008523]| increased IgG1 level [MP:0008567]| absent lymph node germinal center [MP:0008596]| decreased interferon-gamma secretion [MP:0008660]| increased circulating interleukin-6 level [MP:0008661]| increased interleukin-10 secretion [MP:0008663]| decreased interleukin-10 secretion [MP:0008681]| increased interleukin-12 secretion [MP:0008687]| increased interleukin-17 secretion [MP:0008699]| increased interleukin-2 secretion [MP:0008702]| increased interleukin-4 secretion [MP:0008713]| increased interleukin-5 secretion [MP:0008770]| abnormal cytokine level [MP:0008828]| decreased survivor rate [MP:0008874]| abnormal lymph node cell ratio [MP:0009099]| decreased physiological sensitivity to xenobiotic [MP:0009246]| abnormal uterine NK cell physiology [MP:0009336]| pale spleen [MP:0009394]| increased splenocyte proliferation [MP:0009419]| increased uterine NK cell number [MP:0009643]| skeletal muscle fibrosis [MP:0009763]| abnormal urine homeostasis [MP:0009766]| increased sensitivity to induced morbidity/mortality [MP:0009788]| increased sensitivity to xenobiotic induced morbidity/mortality [MP:0009791]| increased susceptibility to bacterial infection induced morbidity/mortality [MP:0009828]| increased susceptibility to viral infection induced morbidity/mortality [MP:0010210]| increased tumor latency [MP:0010308]| abnormal circulating cytokine level [MP:0010574]| decreased tumor latency [MP:0010639]| aorta dilation [MP:0010659]| altered tumor pathology [MP:0010740]| abdominal aorta aneurysm [MP:0010750]| abnormal dendritic cell chemotaxis [MP:0010751]| increased susceptibility to parasitic infection induced morbidity/mortality [MP:0010760]| decreased susceptibility to parasitic infection induced morbidity/mortality [MP:0010766]| abnormal macrophage chemotaxis [MP:0011086]| abnormal NK cell physiology [MP:0011320]| postnatal lethality [MP:0011427]| incomplete penetrance [MP:0012431]| abnormal glomerular capillary morphology [MP:0013239]| mesangial cell hyperplasia [MP:0013590]| increased lymphoma incidence [MP:0030466]| abnormal cytokine secretion [MP:0003009]| thyroid inflammation [MP:0003504]| insulitis [MP:0004031]| decreased susceptibility to autoimmune diabetes [MP:0004804]| periinsulitis [MP:0005580]| decreased physiological sensitivity to xenobiotic [MP:0008874] | Ifng||EGFP||HBEGF|Foxp3||Ighm|| | 037354-MU | Targeted Mutation | Mutant Mouse Resource and Research Center (MMRRC) | MMRRC | MMRRC_37354-MU, MMRRC_037354, MMRRC_37354 | 2026-09-05 04:09:28 | 0 | ||||
|
B6.129P2-Tlr2/Tlr4/Tlr9tm1Aki/Obs Resource Report Resource Website 1+ mentions Issue |
RRID:IMSR_OBS:21 | Mus musculus |
TLR2/4/9 Triple KO C57BL/6. B6.129P2-Tlr2 |
gene symbol note: toll-like receptor 9|toll-like receptor 2|toll-like receptor 4; mutant strain|congenic strain: Tlr9|Tlr2|Tlr4 | toll-like receptor 9|toll-like receptor 2|toll-like receptor 4 | targeted mutation 1; Shizuo Akira | OBS:21 | Oriental BioService, Inc. | OBS | embryo | 2026-09-04 10:32:37 | 2 | ||||
|
B6.129P2-Tlr2/Tlr4tm1Aki/Obs Resource Report Resource Website Issue |
RRID:IMSR_OBS:19 | Mus musculus |
B6.129P2-Tlr2 |
gene symbol note: toll-like receptor 4|toll-like receptor 2; mutant strain|congenic strain: Tlr4|Tlr2 | toll-like receptor 4|toll-like receptor 2 | targeted mutation 1; Shizuo Akira | OBS:19 | Oriental BioService, Inc. | OBS | embryo | 2026-09-04 10:32:37 | 0 | ||||
|
B6.129S2-Ighmtm1Cgn/CgnOrl Resource Report Resource Website 1+ mentions Issue Issue |
RRID:IMSR_EM:00001 | Mus musculus | muMT<0>(muKO) | gene symbol note: immunoglobulin heavy constant mu; mutant strain: Ighm | immunoglobulin heavy constant mu | targeted mutation 1; University of Cologne | EM:00001 | European Mouse Mutant Archive | EMMA | embryo | 2026-09-04 10:32:38 | 5 |
Can't find your Organism?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. If you want to find a specific organism, it's easier to enter an RRID or a Catalog Number to search. You can refine the search results using Facets on the left side of the search results page. If you are on the table view, you can also search in a specific column by clicking the column title and enter the keywords.
If you still could not find your organism in the search results, please help us by registering it into the system — it's easy. Organisms identifiers are registered through multiple sources depending on the species:
Welcome to the kravitz2 Resources search. From here you can search through a compilation of resources used by kravitz2 and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that kravitz2 has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on kravitz2 then you can log in from here to get additional features in kravitz2 such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into kravitz2 you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
Data set from Kravitz, Owen and Kretizer's 2012 paper "Optogenetic identification of striatal projection neuron subtypes during in vivo recordings."
